^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    aspirin

    Associations

    News

    Trials
    Company:
    Generic mfg.
    Drug class:
    COX inhibitor
    Related drugs:
    Associations

    News

    Trials
    1d
    POPS or POP02: Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) (clinicaltrials.gov)
    P=N/A, N=5000, Recruiting, Duke University | Trial primary completion date: Sep 2026 --> Mar 2027
    Trial primary completion date
    |
    dexamethasone • metformin • Actemra IV (tocilizumab) • Ilaris (canakinumab) • Kevzara (sarilumab) • Kineret (anakinra) • Orencia (abatacept) • Valcyte (valganciclovir) • aspirin
    6d
    ATILA Project: Aspirin Versus Tirofiban in Endovascular Treatment for Patients With Acute Ischemic Stroke Due to Tandem Lesion (clinicaltrials.gov)
    P4, N=240, Completed, Fundación Pública Andaluza para la gestión de la Investigación en Sevilla | Active, not recruiting --> Completed
    Trial completion
    |
    aspirin
    6d
    R7508-DVT-24120: REGN7508 versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis after Total Knee Arthroplasty in Adult Participants (2025-520479-25-00)
    P2/3, N=40, Not yet recruiting, Regeneron Pharmaceuticals Inc.
    New P2/3 trial
    |
    aspirin
    7d
    Hematologic responses with favorable safety in three elderly patients with polycythemia vera treated with ropeginterferon alfa-2b (PubMed, Rinsho Ketsueki)
    The standard treatment is low-dose aspirin and phlebotomy, with cytoreductive therapy added for high-risk PV. All 3 patients achieved and maintained complete hematologic response with reduced JAK2 V617F allele burden. Ropeg-IFN is an effective and safe therapy for elderly patients with PV that also improves quality of life.
    Journal
    |
    JAK2 (Janus kinase 2)
    |
    Besremi (ropeginterferon alfa-2b-njft) • aspirin
    7d
    Gastric intramural hematoma during treatment with aspirin and anagrelide in a patient with essential thrombocythemia (PubMed, Rinsho Ketsueki)
    Although thrombosis prevention is crucial in ET, anagrelide is associated with a higher risk of bleeding events than other therapies. To our knowledge, this is the first reported case of gastric intramural hematoma associated with ET and anagrelide.
    Journal
    |
    JAK2 (Janus kinase 2)
    |
    aspirin
    9d
    Add-Aspirin: A Trial Assessing the Effects of Aspirin on Disease Recurrence and Survival After Primary Therapy in Common Non Metastatic Solid Tumours (clinicaltrials.gov)
    P3, N=11000, Active, not recruiting, University College, London | Not yet recruiting --> Active, not recruiting
    Enrollment closed
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    HER-2 positive • ER positive • HR positive • HER-2 negative • HR negative • ER negative • HER-2 negative + ER positive • HER-2 negative + HR negative
    |
    aspirin
    9d
    PI20/01514: Effect of obesity due to the action of aspirin and its effectiveness in therapy for the treatment of colon cancer. (2024-515251-37-00)
    P1/2, N=60, Recruiting, Fundacion Instituto De Investigacion Sanitaria Aragon | Not yet recruiting --> Recruiting
    Enrollment open
    |
    aspirin • omeprazole
    11d
    The Impact of Factor Xa Inhibition on Thrombosis, Platelet Activation, and Endothelial Function in Peripheral Artery Disease (clinicaltrials.gov)
    P4, N=60, Completed, Vanderbilt University Medical Center | Active, not recruiting --> Completed | Trial completion date: Mar 2026 --> Jul 2025 | Trial primary completion date: Mar 2026 --> Jul 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    ICAM1 (Intercellular adhesion molecule 1)
    |
    aspirin
    11d
    IRELAnD: Investigating the Role of Early Low-dose Aspirin in Diabetes (clinicaltrials.gov)
    P3, N=137, Completed, Royal College of Surgeons, Ireland | N=300 --> 137 | Unknown status --> Completed
    Trial completion • Enrollment change
    |
    aspirin
    11d
    Effect of Anticoagulant Therapy on Endometrial Receptivity and Pregnancy Outcomes in Infertility (clinicaltrials.gov)
    P=N/A, N=300, Recruiting, Tang-Du Hospital
    New trial
    |
    aspirin
    13d
    PEAR1/EAF1 deficiency impairs aspirin responsiveness in atherosclerotic endothelium: A novel mechanism of atypical aspirin resistance. (PubMed, Microvasc Res)
    The PEAR1/EAF1 interaction ameliorates aspirin resistance in atherosclerosis. This effect is associated with suppression of the endothelial NF-κB/NLRP3 inflammatory signaling pathway and altered endothelial cell fate under inflammatory stress. Targeting the PEAR1/EAF1 interaction represents a novel potential therapeutic strategy for overcoming AR.
    Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • NLRP3 (NLR Family Pyrin Domain Containing 3) • RELA (RELA Proto-Oncogene)
    |
    aspirin
    13d
    AntiPlatelet theraPy stratEgy followiNg Left Atrial appenDAGe closurE (clinicaltrials.gov)
    P4, N=60, Recruiting, University Hospital, Bordeaux | Not yet recruiting --> Recruiting
    Enrollment open
    |
    aspirin